Date: June 2026 PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC13310799/ Category: N/A Authors: Toru Sakatani, Sunao Tanaka, Kaoru Murakami, Cynthia Jinno, Francisco Aguilar, Catherine Bresee, Owen T M Chan, Daniel J Luthringer, Alberto Contreras-Sanz, Peter Black, Charles J Rosser, Hideki Furuya Abstract: The CXCR2-CXCL1 axis is critical in tumorigenesis, specifically, CXCL1 is a secreted chemokine implicated in tumor progression, angiogenesis, and immune modulation. A

Date: August 10, 2026 PMID: 42573944 Category: N/A Authors: Kai Chen, Yixuan Zhao, Kentaro Takeda, Ying Yuan Abstract: The US Food and Drug Administration (FDA) launched Project Optimus and issued guidance to reform dose-finding and selection trials, shifting the paradigm from identifying the maximum tolerated dose (MTD) to determining the optimal biological dose (OBD), which optimizes the risk and benefit of treatments. The FDA's guidance emphasizes the importance of co

Date: May 18, 2026 PMID: https://pmc.ncbi.nlm.nih.gov/articles/PMC13352979/ Category: N/A Authors: Zhiyong He, Yves Konigshofer, Russell Garlick, Jayanthi Ramprakash, Madhumita Ramesh, Eric Hall, Adam Corner, Michelle Clarissa, Jocelyn H Wright, Victoria K Cannon, Ming Yu, William M Grady, Cecilia C S Yeung, Zachary Heimer, Zhili Wang, ShiPing Zou, Shidong Jia, Fang Liu, Giancarlo Bonora, Karol Bomsztyk, Daniel Mar, Kenneth D Cole, Hua-Jun He Abstract: Background: Aberra